DATA SCIENCE, AI, AND MACHINE LEARNING IN DRUG DEVELOPMENT
ebook

DATA SCIENCE, AI, AND MACHINE LEARNING IN DRUG DEVELOPMENT (ebook)

HARRY YANG

$1,480.00
IVA incluido
Editorial:
CHAPMAN & HALL
Materia
MEDICINA GRAL
ISBN:
9781000652697
Formato:
Epublication content package
Idioma:
Inglés
DRM
Si

The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise

Otros libros del autor

  • REAL-WORLD EVIDENCE IN DRUG DEVELOPMENT AND EVALUATION
    HARRY YANG
    Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book syst...

    $1,100.00

  • EMERGING NON-CLINICAL BIOSTATISTICS IN BIOPHARMACEUTICAL DEVELOPMENT AND MANUFACTURING
    HARRY YANG
    The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-d...

    $1,380.00